COBENFY - (20MG;50MG, 20MG;100MG, 30MG;125MG ; Capsule)

Generic Name	TROSPIUM CHLORIDE; XANOMELINE TARTRATE	**Innovator**	BRISTOL MYERS SQUIBB
Dosage	20MG;50MG, 20MG;100MG, 30MG;125MG ; Capsule	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	More Than 5	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	COBENFY is a combination of xanomeline, a muscarinic agonist, and trospium chloride, a muscarinic antagonist, indicated for the treatment of schizophrenia in adults.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.